Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine

Proteasome inhibitors are moieties targeting the proteolytic activity of a proteasome, with demonstrated efficacy in certain hematological malignancies and candidate drugs in other types of cancer, including glioblastoma (GBM). They disturb the levels of proteasome-regulated proteins and lead to the...

Descripción completa

Detalles Bibliográficos
Autor principal: Gozdz, Agata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670062/
https://www.ncbi.nlm.nih.gov/pubmed/37999122
http://dx.doi.org/10.3390/curroncol30110702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670062/
https://www.ncbi.nlm.nih.gov/pubmed/37999122
http://dx.doi.org/10.3390/curroncol30110702

Ejemplares similares